Michael P. Hill

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

Katarzyna Sieradzan, Susan H. Fox, Michael P. Hill et al. · Neurology · 2001 · 336 citations

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

Vincenzo Di Marzo, Michael P. Hill, Tiziana Bisogno et al. · The FASEB Journal · 2000 · 304 citations

A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease

Mario van der Stelt, Susan H. Fox, Michael P. Hill et al. · The FASEB Journal · 2005 · 199 citations

Neurotransmitter, Cannabinoid Pharmacology, Social Sciences +16

Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

Susan H. Fox, Brian Henry, Michael P. Hill et al. · Movement Disorders · 2002 · 162 citations

Fipamezole (JP‐1730) is a potent α₂ adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease

Juha‐Matti Savola, Michael P. Hill, Mia Engström et al. · Movement Disorders · 2003 · 155 citations

Psychotropic Medication, Pharmacotherapy, Levodopa‐induced Dyskinesia +16